Lipoprotein (a): Impact by ethnicity and environmental and medical conditions

Journal of Lipid Research

Volumn 57, Issue 7, 2016, Pages 1111-1125

  Enkhmaa, Byambaa ^a   Anuurad, Erdembileg ^a   Berglund, Lars ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Apolipoprotein (a) size; Demographic and clinical characteristics; Diabetes; Genetics; Kidney and liver disease; Supplementary key words populations

Indexed keywords

APOLIPOPROTEIN A; C REACTIVE PROTEIN; FIBRINOGEN; LIPOPROTEIN A; SERUM AMYLOID A; APOLIPOPROTEIN B;

AGE DISTRIBUTION; APO(A) GENE; BLACK PERSON; BODY MASS; CARBOHYDRATE DIET; CAUCASIAN; COPY NUMBER VARIATION; DIABETES MELLITUS; ENVIRONMENTAL IMPACT; ETHNIC DIFFERENCE; EXERCISE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME SIZE; HETEROZYGOSITY; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; LOW FAT DIET; LPA GENE; MENOPAUSE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; BLOOD; ETHNIC GROUP; FEMALE; GENETIC VARIATION; GENETICS; HUMAN; KRINGLE DOMAIN; MALE; RISK FACTOR; SEXUAL DEVELOPMENT;

AGE FACTORS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; ETHNIC GROUPS; FEMALE; GENETIC VARIATION; HUMANS; KRINGLES; LIPOPROTEIN(A); MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84977137793     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R051904     Document Type: Review

References (253)

1. Dahlén, G., K. Berg, T. Gillnäs, and C. Ericson. 1975. Lp(a) lipoprotein/pre-beta1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin. Genet. 7: 334-341.
2. Frick, M. H., G. Dahlen, K. Berg, M. Valle, and P. Hekali. 1978. Serum lipids in angiographically assessed coronary atherosclerosis. Chest. 73: 62-65.
3. Berg, K., G. Dahlen, and A. L. Borresen. 1979. Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin. Genet. 16: 347-352.
4. Kostner, G. M., P. Avogaro, G. Cazzolato, E. Marth, G. Bittolo-Bon, and G. B. Qunici. 1981. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 38: 51-61.
5. Guyton, J. R., G. H. Dahlen, W. Patsch, J. A. Kautz, and A. M. Gotto, Jr. 1985. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 5: 265-272.
6. Parra, H. J., I. Luyeye, C. Bouramoue, C. Demarquilly, and J. C. Fruchart. 1987. Black-white differences in serum Lp(a) lipoprotein levels. Clin. Chim. Acta. 168: 27-31.
7. Utermann, G. 1989. The mysteries of lipoprotein(a). Science. 246: 904-910.
8. Marcovina, S. M., J. J. Albers, E. Wijsman, Z. Zhang, N. H. Chapman, and H. Kennedy. 1996. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J. Lipid Res. 37: 2569-2585.
9. Banerjee, D., E. C. Wong, J. Shin, S. P. Fortmann, and L. Palaniappan. 2011. Racial and ethnic variation in lipoprotein (a) levels among Asian Indian and Chinese patients. J. Lipids. 2011: 291954.
10. Sandholzer, C., D. M. Hallman, N. Saha, G. Sigurdsson, C. Lackner, A. Csaszar, E. Boerwinkle, and G. Utermann. 1991. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum. Genet. 86: 607-614.
11. Helmhold, M., J. Bigge, R. Muche, J. Mainoo, J. Thiery, D. Seidel, and V. W. Armstrong. 1991. Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation. J. Lipid Res. 32: 1919-1928.
12. Srinivasan, S. R., G. H. Dahlen, R. A. Jarpa, L. S. Webber, and G. S. Berenson. 1991. Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation. 84: 160-167.
13. Knapp, R. G., P. J. Schreiner, S. E. Sutherland, J. E. Keil, G. E. Gilbert, R. L. Klein, C. Hames, and H. A. Tyroler. 1993. Serum lipoprotein(a) levels in elderly black and white men in the Charleston Heart Study. Clin. Genet. 44: 225-231.
14. Haffner, S. M., K. K. Gruber, P. A. Morales, H. P. Hazuda, R. A. Valdez, B. D. Mitchell, and M. P. Stern. 1992. Lipoprotein(a) concentrations in Mexican Americans and non-Hispanic whites: the San Antonio Heart Study. Am. J. Epidemiol. 136: 1060-1068.
15. Guan, W., J. Cao, B. T. Steffen, W. S. Post, J. H. Stein, M. C. Tattersall, J. D. Kaufman, J. P. McConnell, D. M. Hoefner, R. Warnick, et al. 2015. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 35: 996-1001.
16. McLean, J. W., J. E. Tomlinson, W. J. Kuang, D. L. Eaton, E. Y. Chen, G. M. Fless, A. M. Scanu, and R. M. Lawn. 1987. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330: 132-137.
17. Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler. Thromb. Vasc. Biol. 24: 2219-2226.
18. Lackner, C., E. Boerwinkle, C. C. Leffert, T. Rahmig, and H. H. Hobbs. 1991. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87: 2153-2161.
19. Lackner, C., J. C. Cohen, and H. H. Hobbs. 1993. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum. Mol. Genet. 2: 933-940.
20. Marcovina, S. M., Z. H. Zhang, V. P. Gaur, and J. J. Albers. 1993. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem. Biophys. Res. Commun. 191: 1192-1196.
21. Rubin, J., F. Paultre, C. H. Tuck, S. Holleran, R. G. Reed, T. A. Pearson, C. M. Thomas, R. Ramakrishnan, and L. Berglund. 2002. Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J. Lipid Res. 43: 234-244.
22. Marcovina, S. M., J. J. Albers, B. Gabel, M. L. Koschinsky, and V. P. Gaur. 1995. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin. Chem. 41: 246-255.
23. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90: 52-60.
24. Rao, F., A. J. Schork, A. X. Maihofer, C. M. Nievergelt, S. M. Marcovina, E. R. Miller, J. L. Witztum, D. T. O'Connor, and S. Tsimikas. 2015. Heritability of biomarkers of oxidized lipoproteins: twin pair study. Arterioscler. Thromb. Vasc. Biol. 35: 1704-1711.
25. Scholz, M., H. G. Kraft, A. Lingenhel, R. Delport, E. H. Vorster, H. Bickeboller, and G. Utermann. 1999. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur. J. Hum. Genet. 7: 169-178.
26. Chretien, J. P., J. Coresh, Y. Berthier-Schaad, W. H. Kao, N. E. Fink, M. J. Klag, S. M. Marcovina, F. Giaculli, and M. W. Smith. 2006. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J. Med. Genet. 43: 917-923.
27. Trommsdorff, M., S. Kochl, A. Lingenhel, F. Kronenberg, R. Delport, H. Vermaak, L. Lemming, I. C. Klausen, O. Faergeman, G. Utermann, et al. 1995. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J. Clin. Invest. 96: 150-157.
28. Rubin, J., H. J. Kim, T. A. Pearson, S. Holleran, R. Ramakrishnan, and L. Berglund. 2006. Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo. [a] J. Lipid Res. 47: 982-989.
29. Lanktree, M. B., S. S. Anand, S. Yusuf, and R. A. Hegele. 2010. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet. 3: 39-46.
30. Luke, M. M., J. P. Kane, D. M. Liu, C. M. Rowland, D. Shiffman, J. Cassano, J. J. Catanese, C. R. Pullinger, D. U. Leong, A. R. Arellano, et al. 2007. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27: 2030-2036.
31. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
32. Ronald, J., R. Rajagopalan, F. Cerrato, A. S. Nord, T. Hatsukami, T. Kohler, S. Marcovina, P. Heagerty, and G. P. Jarvik. 2011. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke. 42: 2-9.
33. Zabaneh, D., M. Kumari, M. Sandhu, N. Wareham, N. Wainwright, T. Papamarkou, J. Hopewell, R. Clarke, K. Li, J. Palmen, et al. 2011. Meta analysis of candidate gene variants outside the LPA locus with Lp(a) plasma levels in 14,500 participants of six White European cohorts. Atherosclerosis. 217: 447-451.
34. Thanassoulis, G., C. Y. Campbell, D. S. Owens, J. G. Smith, A. V. Smith, G. M. Peloso, K. F. Kerr, S. Pechlivanis, M. J. Budoff, T. B. Harris, et al. 2013. Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368: 503-512.
35. Dumitrescu, L., K. Glenn, K. Brown-Gentry, C. Shephard, M. Wong, M. J. Rieder, J. D. Smith, D. A. Nickerson, and D. C. Crawford. 2011. Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey. PLoS One. 6: e16604.
36. Schadt, E. E., C. Molony, E. Chudin, K. Hao, X. Yang, P. Y. Lum, A. Kasarskis, B. Zhang, S. Wang, C. Suver, et al. 2008. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6: e107.
37. Lu, W., Y. C. Cheng, K. Chen, H. Wang, G. S. Gerhard, C. D. Still, X. Chu, R. Yang, A. Parihar, J. R. O'Connell, et al. 2015. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum. Mol. Genet. 24: 2390-2400.
38. Ober, C., A. S. Nord, E. E. Thompson, L. Pan, Z. Tan, D. Cusanovich, Y. Sun, R. Nicolae, C. Edelstein, D. H. Schneider, et al. 2009. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J. Lipid Res. 50: 798-806.
39. Newman, D. L., S. Hoffjan, C. Bourgain, M. Abney, R. I. Nicolae, E. T. Profits, M. A. Grow, K. Walker, L. Steiner, R. Parry, et al. 2004. Are common disease susceptibility alleles the same in outbred and founder populations? Eur. J. Hum. Genet. 12: 584-590.
40. Deo, R. C., J. G. Wilson, C. Xing, K. Lawson, W. H. Kao, D. Reich, A. Tandon, E. Akylbekova, N. Patterson, T. H. Mosley, Jr., et al. 2011. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One. 6: e14581.
41. Kivimäki, M., C. G. Magnussen, M. Juonala, M. Kähönen, J. Kettunen, B. M. Loo, T. Lehtimäki, J. Viikari, and O. T. Raitakari. 2011. Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study. Int. J. Epidemiol. 40: 470-478.
42. Qi, Q., T. Workalemahu, C. Zhang, F. B. Hu, and L. Qi. 2012. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur. Heart J. 33: 325-334.
43. López, S., A. Buil, J. Ordoñez, J. C. Souto, L. Almasy, M. Lathrop, J. Blangero, F. Blanco-Vaca, J. Fontcuberta, and J. M. Soria. 2008. Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. Eur. J. Hum. Genet. 16: 1372-1379.
44. Berthold, H. K., M. Laudes, W. Krone, and I. Gouni-Berthold. 2011. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One. 6: e24719.
45. Labeur, C., G. Michiels, J. Bury, D. C. Usher, and M. Rosseneu. 1989. Lipoprotein(a) quantified by an enzyme-linked immunosorbent assay with monoclonal antibodies. Clin. Chem. 35: 1380-1384.
46. Jenner, J. L., J. M. Ordovas, S. Lamon-Fava, M. M. Schaefer, P. W. Wilson, W. P. Castelli, and E. J. Schaefer. 1993. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 87: 1135-1141.
47. Bovet, P., M. Rickenbach, V. Wietlisbach, W. Riesen, C. Shamlaye, R. Darioli, and B. Burnand. 1994. Comparison of serum lipoprotein(a) distribution and its correlates among black and white populations. Int. J. Epidemiol. 23: 20-27.
48. Slunga, L., K. Asplund, O. Johnson, and G. H. Dahlen. 1993. Lipoprotein (a) in a randomly selected 25-64 year old population: the Northern Sweden Monica Study. J. Clin. Epidemiol. 46: 617-624.
49. Selby, J. V., M. A. Austin, C. Sandholzer, C. P. Quesenberry, Jr., D. Zhang, E. Mayer, and G. Utermann. 1994. Environmental and behavioral influences on plasma lipoprotein(a) concentration in women twins. Prev. Med. 23: 345-353.
50. Berg, K., and O. C. Ro. 1991. Lp(a) lipoprotein level and longevity. Ann. Genet. 34: 264-269.
51. Thillet, J., C. Doucet, J. Chapman, B. Herbeth, D. Cohen, and L. Faure-Delanef. 1998. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis. 136: 389-394.
52. Matsubara, M., H. Akita, H. Shibuya, and H. Chiba. 2001. Decreased longevity in Japanese men, associated with low-molecular-weight apolipoprotein(a) phenotypes. Ann. Clin. Biochem. 38: 120-123.
53. Panza, F., A. D'Introno, C. Capurso, A. M. Colacicco, D. Seripa, A. Pilotto, A. Santamato, A. Capurso, and V. Solfrizzi. 2007. Lipoproteins, vascular-related genetic factors, and human longevity. Rejuvenation Res. 10: 441-458.
54. Lippi, G., G. Targher, G. L. Salvagno, M. Montagnana, M. Franchini, and G. C. Guidi. 2010. Lipoprotein(a) and ageing. Clin. Lab. 56: 463-466.
55. Gaw, A., G. Docherty, E. A. Brown, and I. Ford. 1999. Predictors of plasma lipoprotein(a) concentration in the West of Scotland Coronary Prevention Study cohort. Atherosclerosis. 143: 445-450.
56. Akanji, A. O., A. N. Al-Isa, and L. Thalib. 2011. Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects. Clin. Chem. Lab. Med. 49: 1681-1690.
57. Zlatohlávek, L., K. Zidková, M. Vrablik, T. Haas, M. Prusiková, H. Svobodová, and R. Ceska. 2008. Lipoprotein(a) and its position among other risk factors of atherosclerosis. Physiol. Res. 57: 777-783.
58. Albers, J. J., and W. R. Hazzard. 1974. Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids. 9: 15-26.
59. Cobbaert, C., and H. Kesteloot. 1992. Serum lipoprotein(a) levels in racially different populations. Am. J. Epidemiol. 136: 441-449.
60. Volpato, S., G. B. Vigna, M. M. McDermott, M. Cavalieri, C. Maraldi, F. Lauretani, S. Bandinelli, G. Zuliani, J. M. Guralnik, R. Fellin, et al. 2010. Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). Am. J. Cardiol. 105: 1825-1830.
61. Császár, A., L. Romics, C. Lackner, H. Dieplinger, I. Karádi, and G. Utermann. 1990. Plasma concentration of lipoprotein(a) and distribution of its subtypes in the healthy population of Hungary [Article in Hungarian]. Orv. Hetil. 131: 2071-2075.
62. Nago, N., K. Kayaba, J. Hiraoka, H. Matsuo, T. Goto, K. Kario, A. Tsutsumi, Y. Nakamura, and M. Igarashi. 1995. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am. J. Epidemiol. 141: 815-821.
63. Barra, S., V. Cuomo, N. Silvestri, C. Materazzi, G. Vitagliano, G. Capozzi, S. Caruso, G. Gaeta, and M. Trevisan. 2011. Lipoprotein(a) concentration does not differ between sexes in healthy offspring of patients with premature myocardial infarction. J. Cardiovasc. Med. (Hagerstown). 12: 482-486.
64. Frohlich, J., M. Dobiasova, L. Adler, and M. Francis. 2004. Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease. Physiol. Res. 53: 481-486.
65. Allard, M. D., R. Saeedi, M. Yousefi, and J. Frohlich. 2014. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids Health Dis. 13: 65.
66. Nenseter, M. S., H. W. Lindvig, T. Ueland, G. Langslet, L. Ose, K. B. Holven, and K. Retterstol. 2011. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis. 216: 426-432.
67. Masarei, J. R., I. L. Rouse, W. J. Lynch, K. Robertson, R. Vandongen, and L. J. Beilin. 1984. Effects of a lacto-ovo vegetarian diet on serum concentrations of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). Am. J. Clin. Nutr. 40: 468-478.
68. Brown, S. A., J. Morrisett, J. R. Patsch, R. Reeves, A. M. Gotto, Jr., and W. Patsch. 1991. Influence of short term dietary cholesterol and fat on human plasma Lp[a] and LDL levels. J. Lipid Res. 32: 1281-1289.
69. Berglund, L. 1995. Diet and drug therapy for lipoprotein (a). Curr. Opin. Lipidol. 6: 48-56.
70. Mensink, R. P., P. L. Zock, M. B. Katan, and G. Hornstra. 1992. Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. J. Lipid Res. 33: 1493-1501.
71. Nestel, P., M. Noakes, B. Belling, R. McArthur, P. Clifton, E. Janus, and M. Abbey. 1992. Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet. J. Lipid Res. 33: 1029-1036.
72. Ginsberg, H. N., P. Kris-Etherton, B. Dennis, P. J. Elmer, A. Ershow, M. Lefevre, T. Pearson, P. Roheim, R. Ramakrishnan, R. Reed, et al. 1998. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler. Thromb. Vasc. Biol. 18: 441-449.
73. Silaste, M. L., M. Rantala, G. Alfthan, A. Aro, J. L. Witztum, Y. A. Kesaniemi, and S. Horkko. 2004. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler. Thromb. Vasc. Biol. 24: 498-503.
74. Brousseau, M. E., J. M. Ordovas, R. J. Nicolosi, and E. J. Schaefer. 1994. Effects of dietary fat saturation on plasma lipoprotein(a) and hepatic apolipoprotein(a) mRNA concentrations in cynomolgus monkeys. Atherosclerosis. 106: 109-118.
75. Vega-López, S., N. R. Matthan, L. M. Ausman, M. Ai, S. Otokozawa, E. J. Schaefer, and A. H. Lichtenstein. 2009. Substitution of vegetable oil for a partially-hydrogenated fat favorably alters cardiovascular disease risk factors in moderately hypercholesterolemic postmenopausal women. Atherosclerosis. 207: 208-212.
76. Faghihnia, N., S. Tsimikas, E. R. Miller, J. L. Witztum, and R. M. Krauss. 2010. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J. Lipid Res. 51: 3324-3330.
77. Faraj, M., M. E. Lavoie, L. Messier, J. P. Bastard, and D. Prud'homme. 2010. Reduction in serum apoB is associated with reduced inflammation and insulin resistance in post-menopausal women: A MONET study. Atherosclerosis. 211: 682-688.
78. Haring, B., M. C. von Ballmoos, L. J. Appel, and F. M. Sacks. 2014. Healthy dietary interventions and lipoprotein (a) plasma levels: results from the Omni Heart Trial. PLoS One. 9: e114859.
79. Langsted, A., P. R. Kamstrup, and B. G. Nordestgaard. 2014. Lipoprotein(a): Fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis. 234: 95-101.
80. Lamon-Fava, S., D. Jimenez, J. C. Christian, R. R. Fabsitz, T. Reed, D. Carmelli, W. P. Castelli, J. M. Ordovas, P. W. Wilson, and E. J. Schaefer. 1991. The NHLBI Twin Study: heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and concordance for lipoprotein(a). Atherosclerosis. 91: 97-106.
81. MacAuley, D., E. E. McCrum, G. Stott, A. E. Evans, E. Duly, T. Trinick, K. Sweeney, and C. A. Boreham. 1996. Physical activity, lipids, apolipoproteins, and Lp(a) in the Northern Ireland Health and Activity Survey. Med. Sci. Sports Exerc. 28: 720-736.
82. Israel, R. G., M. J. Sullivan, R. H. Marks, R. S. Cayton, and T. C. Chenier. 1994. Relationship between cardiorespiratory fitness and lipoprotein(a) in men and women. Med. Sci. Sports Exerc. 26: 425-431.
83. Hubinger, L., L. T. Mackinnon, and F. Lepre. 1995. Lipoprotein(a) [Lp(a)] levels in middle-aged male runners and sedentary controls. Med. Sci. Sports Exerc. 27: 490-496.
84. Szymanski, L. M., J. L. Durstine, P. G. Davis, M. Dowda, and R. R. Pate. 1996. Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a). Metabolism. 45: 1427-1433.
85. Halle, M., A. Berg, T. von Stein, M. W. Baumstark, D. Konig, and J. Keul. 1996. Lipoprotein(a) in endurance athletes, power athletes, and sedentary controls. Med. Sci. Sports Exerc. 28: 962-966.
86. Oyelola, O. O., and M. A. Rufai. 1993. Plasma lipid, lipoprotein and apolipoprotein profiles in Nigerian university athletes and non-athletes. Br. J. Sports Med. 27: 271-274.
87. Taimela, S., J. S. Viikari, K. V. Porkka, and G. H. Dahlen. 1994. Lipoprotein (a) levels in children and young adults: the influence of physical activity. The Cardiovascular Risk in Young Finns Study. Acta Paediatr. 83: 1258-1263.
88. Austin, A., V. Warty, J. Janosky, and S. Arslanian. 1993. The relationship of physical fitness to lipid and lipoprotein(a) levels in adolescents with IDDM. Diabetes Care. 16: 421-425.
89. Cardoso, G. C., C. Posadas, O. O. Orvananos, C. Peniche, J. Zamora, R. Aguilar, J. A. Holguin, A. S. Raynaud, J. D. Morrisett, and J. Guevara, Jr. 1994. Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein(a). Chem. Phys. Lipids. 67-68: 207-221.
90. Cohen, L. I., C. G. Hartford, and G. G. Rogers. 1996. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med. Sci. Sports Exerc. 28: 176-179.
91. Hellsten, G., K. Boman, G. Hallmans, and G. Dahlen. 1989. Lipids and endurance physical activity. Atherosclerosis. 75: 93-94.
92. Hubinger, L., and L. T. Mackinnon. 1996. The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males. Med. Sci. Sports Exerc. 28: 757-764.
93. Lobo, R. A., M. Notelovitz, L. Bernstein, F. Y. Khan, R. K. Ross, and W. L. Paul. 1992. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am. J. Obstet. Gynecol. 166: 1182-1188, discussion 1188-1190.
94. Haskell, W. L., E. L. Alderman, J. M. Fair, D. J. Maron, S. F. Mackey, H. R. Superko, P. T. Williams, I. M. Johnstone, M. A. Champagne, R. M. Krauss, et al. 1994. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 89: 975-990.
95. Danesh, J., J. G. Wheeler, G. M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G. D. Lowe, M. B. Pepys, and V. Gudnason. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350: 1387-1397.
96. Danesh, J., S. Lewington, S. G. Thompson, G. D. Lowe, R. Collins, J. B. Kostis, A. C. Wilson, A. R. Folsom, K. Wu, M. Benderly, et al. 2005. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 294: 1799-1809.
97. Uhlar, C. M., and A. S. Whitehead. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265: 501-523.
98. Rolph, M. S., S. Zimmer, B. Bottazzi, C. Garlanda, A. Mantovani, and G. K. Hansson. 2002. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 22: e10-e14.
99. Lavi, S., J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman. 2007. Local production of lipoproteinassociated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 115: 2715-2721.
100. Klezovitch, O., C. Edelstein, and A. M. Scanu. 2001. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain. J. Biol. Chem. 276: 46864-46869.
101. Ramharack, R., D. Barkalow, and M. A. Spahr. 1998. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler. Thromb. Vasc. Biol. 18: 984-990.
102. Müller, N., D. M. Schulte, K. Türk, S. Freitag-Wolf, J. Hampe, R. Zeuner, J. O. Schröder, I. Gouni-Berthold, H. K. Berthold, W. Krone, et al. 2015. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J. Lipid Res. 56: 1034-1042.
103. Bergmark, C., A. Dewan, A. Orsoni, E. Merki, E. R. Miller, M. J. Shin, C. J. Binder, S. Horkko, R. M. Krauss, M. J. Chapman, et al. 2008. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49: 2230-2239.
104. Tsimikas, S., and J. L. Witztum. 2008. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr. Opin. Lipidol. 19: 369-377.
105. Anuurad, E., J. Rubin, A. Chiem, R. P. Tracy, T. A. Pearson, and L. Berglund. 2008. High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans. J. Clin. Endocrinol. Metab. 93: 1482-1488.
106. Enkhmaa, B., E. Anuurad, W. Zhang, T. A. Pearson, and L. Berglund. 2010. Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis. 211: 526-530.
107. Enkhmaa, B., E. Anuurad, Z. Ozturk, W. Zhang, T. A. Pearson, and L. Berglund. 2011. Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Transl. Res. 158: 92-98.
108. Muñoz-Torrero, J. F., D. Rivas, R. Alonso, L. Crespo, A. Costo, M. Roman, C. Martín, and J. Zamorano. 2012. Influence of lipoprotein (a) on inflammatory biomarkers in metabolic syndrome. South. Med. J. 105: 339-343.
109. Salpeter, S. R., J. M. Walsh, T. M. Ormiston, E. Greyber, N. S. Buckley, and E. E. Salpeter. 2006. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 8: 538-554.
110. Ushioda, M., K. Makita, K. Takamatsu, F. Horiguchi, and D. Aoki. 2006. Serum lipoprotein(a) dynamics before/after menopause and long-term effects of hormone replacement therapy on lipoprotein(a) levels in middle-aged and older Japanese women. Horm. Metab. Res. 38: 581-586.
111. Suk Danik, J., N. Rifai, J. E. Buring, and P. M. Ridker. 2008. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J. Am. Coll. Cardiol. 52: 124-131.
112. Wasan, K. M., P. E. Goss, P. H. Pritchard, L. Shepherd, D. Tu, and J. N. Ingle. 2012. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 substudy. Breast Cancer Res. Treat. 136: 769-776.
113. Perrone, G., O. Capri, P. Galoppi, R. Brunelli, E. Bevilacqua, F. Ceci, M. V. Ciarla, and R. Strom. 2009. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. Gynecol. Obstet. Invest. 68: 33-39.
114. Berg, K., B. Roald, and H. Sande. 1994. High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation. Clin. Genet. 46: 52-56.
115. Husby, H., B. Roald, R. Schjetlein, B. I. Nesheim, and K. Berg. 1996. High levels of Lp(a) lipoprotein in a family with cases of severe pre-eclampsia. Clin. Genet. 50: 47-49.
116. Zechner, R., G. Desoye, M. O. Schweditsch, K. P. Pfeiffer, and G. M. Kostner. 1986. Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum. Metabolism. 35: 333-336.
117. Panteghini, M., and F. Pagani. 1991. Serum concentrations of lipoprotein(a) during normal pregnancy and postpartum. Clin. Chem. 37: 2009-2010.
118. Wersch, J. W., B. A. van Mackelenbergh, and J. M. Ubachs. 1994. Lipoprotein(a) in smoking and non-smoking pregnant women. Scand. J. Clin. Lab. Invest. 54: 361-364.
119. Brizzi, P., G. Tonolo, F. Esposito, L. Puddu, S. Dessole, M. Maioli, and S. Milia. 1999. Lipoprotein metabolism during normal pregnancy. Am. J. Obstet. Gynecol. 181: 430-434.
120. Sattar, N., P. Clark, I. A. Greer, J. Shepherd, and C. J. Packard. 2000. Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia. Atherosclerosis. 148: 407-411.
121. Belo, L., M. Caslake, A. Santos-Silva, L. Pereira-Leite, A. Quintanilha, and I. Rebelo. 2002. Lipoprotein(a): a longitudinal versus a cross-sectional study in normal pregnancy and its levels in preeclampsia. Atherosclerosis. 165: 393-395.
122. Manten, G. T., A. Franx, Y. Y. van der Hoek, T. M. Hameeteman, H. A. Voorbij, H. C. Smolders, P. Westers, and G. H. Visser. 2003. Changes of plasma lipoprotein(a) during and after normal pregnancy in Caucasians. J. Matern. Fetal Neonatal Med. 14: 91-95.
123. Lippi, G., A. Albiero, M. Montagnana, G. L. Salvagno, S. Scevarolli, M. Franchi, and G. C. Guidi. 2007. Lipid and lipoprotein profile in physiological pregnancy. Clin. Lab. 53: 173-177.
124. Mazurkiewicz, J. C., G. F. Watts, F. G. Warburton, B. M. Slavin, C. Lowy, and E. Koukkou. 1994. Serum lipids, lipoproteins and apolipoproteins in pregnant non-diabetic patients. J. Clin. Pathol. 47: 728-731.
125. Silliman, K., V. Shore, and T. M. Forte. 1994. Hypertriglyceridemia during late pregnancy is associated with the formation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins. Metabolism. 43: 1035-1041.
126. Chiang, A. N., M. L. Yang, J. H. Hung, P. Chou, S. K. Shyn, and H. T. Ng. 1995. Alterations of serum lipid levels and their biological relevances during and after pregnancy. Life Sci. 56: 2367-2375.
127. Rymer, J., S. Constable, P. Lumb, and M. Crook. 2002. Serum lipoprotein (A) and apolipoproteins during pregnancy and postpartum in normal women. J. Obstet. Gynaecol. 22: 256-259.
128. Uslu, A., T. Uslu, F. Bingol, and S. Aydin. 1996. Lipoprotein levels in patients with pregnancy induced hypertension. Arch. Gynecol. Obstet. 258: 21-24.
129. Wang, J., S. Mimuro, R. Lahoud, B. Trudinger, and X. L. Wang. 1998. Elevated levels of lipoprotein(a) in women with preeclampsia. Am. J. Obstet. Gynecol. 178: 146-149.
130. Bar, J., D. Harell, R. Bardin, J. Pardo, R. Chen, M. Hod, and M. Sullivan. 2002. The elevated plasma lipoprotein(a) concentrations in preeclampsia do not precede the development of the disorder. Thromb. Res. 105: 19-23.
131. Ogunyemi, D., W. Ku, and Y. Arkel. 2002. The association between inherited thrombophilia, antiphospholipid antibodies and lipoprotein A levels with obstetrical complications in pregnancy. J. Thromb. Thrombolysis. 14: 157-162.
132. Aksoy, H., Y. Kumtepe, F. Akcay, and A. K. Yildirim. 2002. Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia. Clin. Exp. Med. 2: 39-43.
133. Mori, M., A. Mori, Y. Saburi, M. Sida, and H. Ohta. 2003. Levels of lipoprotein(a) in normal and compromised pregnancy. J. Perinat. Med. 31: 23-28.
134. Demir, B., S. Demir, Y. Atamer, S. Guven, A. Atamer, Y. Kocyigit, A. Hekimoglu, and G. Toprak. 2011. Serum levels of lipids, lipoproteins and paraoxonase activity in pre-eclampsia. J. Int. Med. Res. 39: 1427-1431.
135. Bayhan, G., Y. Kocyigit, A. Atamer, Y. Atamer, and Z. Akkus. 2005. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia. Gynecol. Endocrinol. 21: 1-6.
136. Parvin, S., L. Samsuddin, A. Ali, S. A. Chowdhury, and I. Siddique. 2010. Lipoprotein (a) level in pre-eclampsia patients. Bangladesh Med. Res. Counc. Bull. 36: 97-99.
137. Nagy, B., J. Rigo, Jr., L. Fintor, L. Romics, Z. Papp, and I. Karadi. 1999. Distribution of apolipoprotein(a) isoforms in normotensive and severe preeclamptic women. J. Matern. Fetal Med. 8: 270-274.
138. Var, A., N. K. Kuscu, F. Koyuncu, B. S. Uyanik, E. Onur, Y. Yildirim, and S. Oruc. 2003. Atherogenic profile in preeclampsia. Arch. Gynecol. Obstet. 268: 45-47.
139. Baksu, B., A. Baksu, I. Davas, A. Akyol, and G. Gulbaba. 2005. Lipoprotein (a) levels in women with pre-eclampsia and in normotensive pregnant women. J. Obstet. Gynaecol. Res. 31: 277-282.
140. Wang, Y., A. K. Walli, A. Schulze, F. Blessing, P. Fraunberger, C. Thaler, D. Seidel, and U. Hasbargen. 2006. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus. Apher. Sci. 35: 103-110.
141. Manten, G. T., M. J. Sikkema, H. A. Voorbij, G. H. Visser, H. W. Bruinse, and A. Franx. 2007. Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction. Hypertens. Pregnancy. 26: 39-50.
142. Catarino, C., I. Rebelo, L. Belo, P. Rocha-Pereira, S. Rocha, E. B. Castro, B. Patricio, A. Quintanilha, and A. Santos-Silva. 2008. Fetal lipoprotein changes in pre-eclampsia. Acta Obstet. Gynecol. Scand. 87: 628-634.
143. Bukan, N., O. Kandemir, T. Nas, O. Gulbahar, A. Unal, and B. Cayci. 2012. Maternal cardiac risks in pre-eclamptic patients. J. Matern. Fetal Neonatal Med. 25: 912-914.
144. Manten, G. T., Y. Y. van der Hoek, J. Marko Sikkema, H. A. Voorbij, T. M. Hameeteman, G. H. Visser, and A. Franx. 2005. The role of lipoprotein (a) in pregnancies complicated by preeclampsia. Med. Hypotheses. 64: 162-169.
145. Kronenberg, F., P. Konig, U. Neyer, M. Auinger, A. Pribasnig, U. Lang, J. Reitinger, G. Pinter, G. Utermann, and H. Dieplinger. 1995. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 6: 110-120.
146. Heimbürger, O., P. Stenvinkel, L. Berglund, A. Tranoeus, and B. Lindholm. 1996. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron. 72: 135-144.
147. Kronenberg, F., G. Utermann, and H. Dieplinger. 1996. Lipoprotein(a) in renal disease. Am. J. Kidney Dis. 27: 1-25.
148. Stenvinkel, P., O. Heimburger, F. Paultre, U. Diczfalusy, T. Wang, L. Berglund, and T. Jogestrand. 1999. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55: 1899-1911.
149. Kronenberg, F. 2014. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin. Exp. Nephrol. 18: 234-237.
150. Thomas, M. E., A. Freestone, Z. Varghese, J. W. Persaud, and J. F. Moorhead. 1992. Lipoprotein(a) in patients with proteinuria. Nephrol. Dial. Transplant. 7: 597-601.
151. Faucher, C., C. Doucet, A. Baumelou, J. Chapman, C. Jacobs, and J. Thillet. 1993. Elevated lipoprotein (a) levels in primary nephrotic syndrome. Am. J. Kidney Dis. 22: 808-813.
152. Wanner, C., D. Rader, W. Bartens, J. Kramer, H. B. Brewer, P. Schollmeyer, and H. Wieland. 1993. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann. Intern. Med. 119: 263-269.
153. Stenvinkel, P., L. Berglund, O. Heimburger, E. Pettersson, and A. Alvestrand. 1993. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 44: 1116-1123.
154. Doucet, C., V. Mooser, S. Gonbert, F. Raymond, J. Chapman, C. Jacobs, and J. Thillet. 2000. Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine. J. Am. Soc. Nephrol. 11: 507-513.
155. Kronenberg, F., A. Lingenhel, K. Lhotta, B. Rantner, M. F. Kronenberg, P. Konig, J. Thiery, M. Koch, A. von Eckardstein, and H. Dieplinger. 2004. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int. 66: 348-354.
156. Li, H. Q., J. Wu, D. M. Niu, Y. H. Shi, C. N. Zhang, and J. J. Wang. 2012. The level of native and oxidized lipoprotein(a) in children with nephrotic syndrome. Clin. Biochem. 45: 101-105.
157. Gansevoort, R. T., J. E. Heeg, F. D. Dikkeschei, D. de Zeeuw, P. E. de Jong, and R. P. Dullaart. 1994. Symptomatic antiprotein-uric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol. Dial. Transplant. 9: 244-250.
158. Kronenberg, F., A. Lingenhel, K. Lhotta, B. Rantner, M. F. Kronenberg, P. Konig, J. Thiery, M. Koch, A. von Eckardstein, and H. Dieplinger. 2004. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 65: 606-612.
159. Kronenberg, F., E. Kuen, E. Ritz, R. Junker, P. Konig, G. Kraatz, K. Lhotta, J. F. Mann, G. A. Muller, U. Neyer, et al. 2000. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 11: 105-115.
160. Appel, G. B., C. B. Blum, S. Chien, C. L. Kunis, and A. S. Appel. 1985. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N. Engl. J. Med. 312: 1544-1548.
161. Cressman, M. D., R. J. Heyka, E. P. Paganini, J. O'Neil, C. I. Skibinski, and H. F. Hoff. 1992. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 86: 475-482.
162. Dieplinger, H., P. Y. Schoenfeld, and C. J. Fielding. 1986. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J. Clin. Invest. 77: 1071-1083.
163. Heimann, P., M. A. Josephson, S. K. Fellner, J. R. Thistlethwaite, Jr., F. P. Stuart, and A. Dasgupta. 1991. Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. Am. J. Nephrol. 11: 470-474.
164. Barbagallo, C. M., M. R. Averna, V. Scafidi, A. Galione, and A. Notarbartolo. 1992. Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis. Nephron. 62: 471-472.
165. Shoji, T., Y. Nishizawa, H. Nishitani, M. Yamakawa, and H. Morii. 1992. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin. Nephrol. 38: 271-276.
166. Hirata, K., S. Kikuchi, K. Saku, S. Jimi, B. Zhang, S. Naito, H. Hamaguchi, and K. Arakawa. 1993. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int. 44: 1062-1070.
167. Webb, A. T., D. A. Reaveley, M. O'Donnell, B. O'Connor, M. Seed, and E. A. Brown. 1993. Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol. Dial. Transplant. 8: 609-613.
168. Fiorini, F., P. Masturzo, M. Mij, and S. Bertolini. 1995. Lipoprotein(a) levels in hemodialysis patients: relation to glucose intolerance and hemodialysis duration. Nephron. 70: 500-501.
169. Gault, M. H., L. L. Longerich, L. Purchase, J. Harnett, and C. Breckenridge. 1995. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron. 70: 155-170.
170. Aggarwal, H. K., D. Jain, M. Lathar, R. K. Yadav, and A. Sawhney. 2010. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. Ren. Fail. 32: 647-652.
171. Parsons, D. S., D. A. Reaveley, D. V. Pavitt, M. Misra, and E. A. Brown. 2003. Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol. Dial. Transplant. 18: 1848-1853.
172. Lin, J., M. P. Reilly, K. Terembula, and F. P. Wilson. 2014. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One. 9: e114397.
173. Querfeld, U., M. Lang, J. B. Friedrich, B. Kohl, W. Fiehn, and K. Scharer. 1993. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr. Res. 34: 772-776.
174. Irish, A. B., L. A. Simons, E. Savdie, J. M. Hayes, and J. Simons. 1992. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust. N. Z. J. Med. 22: 243-248.
175. Buggy, D., A. Breathnach, B. Keogh, T. Cooke, and J. Feely. 1993. Lipoprotein(a) and treatment of chronic renal disease. J. Intern. Med. 234: 453-455.
176. Docci, D., L. Baldrati, C. Capponcini, and C. Feletti. 1994. Serum lipoprotein(a) (Lpa(a)) in haemodialysis patients. Nephrol. Dial. Transplant. 9: 733-734.
177. Rahman, M., W. Yang, S. Akkina, A. Alper, A. H. Anderson, L. J. Appel, J. He, D. S. Raj, J. Schelling, L. Strauss, et al. 2014. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin. J. Am. Soc. Nephrol. 9: 1190-1198.
178. Dieplinger, H., C. Lackner, F. Kronenberg, C. Sandholzer, K. Lhotta, F. Hoppichler, H. Graf, and P. Konig. 1993. Elevated plasma concentrations of lipoprotein(a) in patients with endstage renal disease are not related to the size polymorphism of apolipoprotein(a). J. Clin. Invest. 91: 397-401.
179. Milionis, H. J., M. S. Elisaf, A. Tselepis, E. Bairaktari, S. A. Karabina, and K. C. Siamopoulos. 1999. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am. J. Kidney Dis. 33: 1100-1106.
180. Zimmermann, J., S. Herrlinger, A. Pruy, T. Metzger, and C. Wanner. 1999. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 55: 648-658.
181. Gambhir, J. K., O. P. Kalra, A. Khaira, and H. Kaur. 2013. Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysis. Indian J. Nephrol. 23: 18-23.
182. Auguet, T., M. Senti, J. Rubies-Prat, A. Pelegri, J. Pedro-Botet, X. Nogues, and R. Romero. 1993. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein (a) genetic polymorphism. Nephrol. Dial. Transplant. 8: 1099-1103.
183. De Sain-Van Der Velden, M. G., D. J. Reijngoud, G. A. Kaysen, M. M. Gadellaa, H. Voorbij, F. Stellaard, H. A. Koomans, and T. J. Rabelink. 1998. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J. Am. Soc. Nephrol. 9: 1474-1481.
184. Kronenberg, F., P. Konig, K. Lhotta, D. Ofner, C. Sandholzer, R. Margreiter, E. Dosch, G. Utermann, and H. Dieplinger. 1994. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler. Thromb. 14: 1399-1404.
185. Azrolan, N., C. D. Brown, L. Thomas, T. Hayek, Z. H. Zhao, K. G. Roberts, C. Scheiner, and E. A. Friedman. 1994. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler. Thromb. 14: 1393-1398.
186. Black, I. W., and D. E. Wilcken. 1992. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin. Chem. 38: 353-357.
187. Murphy, B. G., and P. T. McNamee. 1992. Apolipoprotein (a) concentration decreases following renal transplantation. Nephrol. Dial. Transplant. 7: 174-175.
188. Kronenberg, F., P. Konig, K. Lhotta, A. Konigsrainer, C. Sandholzer, G. Utermann, and H. Dieplinger. 1993. Cyclosporin and serum lipids in renal transplant recipients. Lancet. 341: 765; author reply 767.
189. Yang, C. W., Y. S. Kim, S. Y. Kim, Y. S. Chang, Y. S. Yoon, and B. K. Bang. 1994. Serum levels of lipoprotein (a) after renal transplantation: short-term follow-up. Nephron. 67: 364.
190. Segarra, A., P. Chacon, M. Martin, M. Vilardell, J. Vila, M. Cotrina, J. Fort, A. Olmos, and L. L. Piera. 1995. Serum lipoprotein (a) levels in patients with chronic renal failure-evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study. Nephron. 69: 9-13.
191. Murphy, B. G., A. Yong, J. H. Brown, and P. T. McNamee. 1995. Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis. 116: 241-245.
192. von Ahsen, N., M. Helmhold, T. Eisenhauer, V. W. Armstrong, and M. Oellerich. 1996. Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. Eur. J. Clin. Invest. 26: 668-675.
193. Kerschdorfer, L., P. Konig, U. Neyer, C. Bosmuller, K. Lhotta, M. Auinger, M. Hohenegger, P. Riegler, R. Margreiter, G. Utermann, et al. 1999. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis. 144: 381-391.
194. Brown, J. H., N. Anwar, C. D. Short, D. Bhatnager, M. I. Mackness, L. P. Hunt, and P. N. Durrington. 1993. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol. Dial. Transplant. 8: 863-867.
195. Süleymanlar, G., T. Ozben, M. Sapan, H. Yilmaz, G. Yakupoglu, and T. Karpuzoglu. 1994. Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a). Transplant. Proc. 26: 2637-2638.
196. Sugahara, S., I. Koyama, Y. Yoshikawa, Y. Dohi, and R. Omoto. 1994. Lipid and lipoprotein(a) in renal transplant recipients. Transplant. Proc. 26: 2080-2081.
197. Webb, A. T., D. A. Reaveley, M. O'Donnell, B. O'Connor, M. Seed, and E. A. Brown. 1993. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet. 341: 268-270.
198. Islam, M. S., J. M. Bard, P. Le Pogamp, D. Leglise, B. Bourbigot, J. Rivalan, and J. Cledes. 1994. Serum lipoprotein (a) in renal transplant recipients treated with cyclosporin monotherapy compared to conventional treatment. Nephrol. Dial. Transplant. 9: 332-333.
199. Lye, W. C., K. Hughes, S. O. Leong, C. C. Tan, and E. J. Lee. 1995. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant. Proc. 27: 977-978.
200. Barbagallo, C. M., M. R. Averna, V. Sparacino, A. Galione, F. Caputo, V. Scafidi, S. Amato, C. Mancino, A. B. Cefalu, and A. Notarbartolo. 1993. Lipoprotein (a) levels in end-stage renal failure and renal transplantation. Nephron. 64: 560-564.
201. Segarra, A., P. Chacon, M. Vilardell, and L. L. Piera. 1993. Cyclosporin and serum lipids in renal transplant recipients. Lancet. 341: 766; author reply 767.
202. Sentí, M., J. M. Puig, J. Lloveras, C. Aubó, M. Mir, F. Barbosa, A. Oliveras, and J. Masramón. 1997. Effect of cyclosporine on serum lipoprotein(a) levels in renal transplant recipients. Transplant. Proc. 29: 2404-2405.
203. Moore, R., D. Thomas, E. Morgan, D. Wheeler, P. Griffin, J. Salaman, and A. Rees. 1993. Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant. Proc. 25: 1060-1061.
204. Wheeler, D. C., R. Morgan, D. M. Thomas, M. Seed, A. Rees, and R. H. Moore. 1996. Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients. Transpl. Int. 9: 221-226.
205. Bell, A. W. 1979. Lipid metabolism in liver and selected tissues and in the whole body of ruminant animals. Prog. Lipid Res. 18: 117-164.
206. Tietge, U. J., K. H. Boker, M. J. Bahr, S. Weinberg, R. Pichlmayr, H. H. Schmidt, and M. P. Manns. 1998. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology. 45: 2255-2260.
207. Hoover-Plow, J., and M. Huang. 2013. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 62: 479-491.
208. Anuurad, E., B. Enkhmaa, and L. Berglund. 2010. Enigmatic role of lipoprotein(a) in cardiovascular disease. Clin. Transl. Sci. 3: 327-332.
209. Motta, M., I. Giugno, P. Ruello, G. Pistone, I. Di Fazio, and M. Malaguarnera. 2001. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med. 92: 301-305.
210. Malaguarnera, M., I. Giugno, B. A. Trovato, M. P. Panebianco, R. Siciliano, and P. Ruello. 1995. Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin. Ther. 17: 721-728.
211. Gregory, W. L., F. L. Game, M. Farrer, J. R. Idle, M. F. Laker, and O. F. James. 1994. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis. 105: 43-50.
212. Irshad, M. 2004. Serum lipoprotein (a) levels in liver diseases caused by hepatitis. Indian J. Med. Res. 120: 542-545.
213. Jiang, J., X. Zhang, C. Wu, X. Qin, G. Luo, H. Deng, M. Lu, B. Xu, M. Li, M. Ji, et al. 2008. Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases. Lipids Health Dis. 7: 25.
214. Van Wersch, J. W. 1994. The behaviour of lipoprotein(a) in patients with various diseases. Scand. J. Clin. Lab. Invest. 54: 559-562.
215. Alessandri, C., S. Basili, M. Maurelli, P. Andreozzi, F. Violi, and C. Cordova. 1994. Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. Clin. Chim. Acta. 224: 125-129.
216. Geiss, H. C., M. M. Ritter, W. O. Richter, P. Schwandt, and R. Zachoval. 1996. Low lipoprotein (a) levels during acute viral hepatitis. Hepatology. 24: 1334-1337.
217. Selvais, P., J. Henrion, M. Schapira, G. Derue, J. C. Hondekijn, A. Parfonry, and F. R. Heller. 1995. Lipoprotein (a) in liver diseases. Correlation between low levels and liver function [Article in French]. Presse Med. 24: 382-386.
218. Kervinen, K., M. J. Savolainen, and Y. A. Kesaniemi. 1991. A rapid increase in lipoprotein (a) levels after ethanol withdrawal in alcoholic men. Life Sci. 48: 2183-2188.
219. Marth, E., G. Cazzolato, G. Bittolo Bon, P. Avogaro, and G. M. Kostner. 1982. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann. Nutr. Metab. 26: 56-62.
220. Lecomte, E., B. Herbeth, F. Paille, J. Steinmetz, Y. Artur, and G. Siest. 1996. Changes in serum apolipoprotein and lipoprotein profile induced by chronic alcohol consumption and withdrawal: determinant effect on heart disease? Clin. Chem. 42: 1666-1675.
221. Clevidence, B. A., M. E. Reichman, J. T. Judd, R. A. Muesing, A. Schatzkin, E. J. Schaefer, Z. Li, J. Jenner, C. C. Brown, M. Sunkin, et al. 1995. Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study. Arterioscler. Thromb. Vasc. Biol. 15: 179-184.
222. Schröder, H., O. Ferrández, J. Jimenez Conde, A. Sánchez-Font, and J. Marrugat. 2005. Cardiovascular risk profile and type of alcohol beverage consumption: a population-based study. Ann. Nutr. Metab. 49: 100-106.
223. Chiva-Blanch, G., M. Urpi-Sarda, E. Ros, P. Valderas-Martinez, R. Casas, S. Arranz, M. Guillen, R. M. Lamuela-Raventos, R. Llorach, C. Andres-Lacueva, et al. 2013. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin. Nutr. 32: 200-206.
224. Droste, D. W., C. Iliescu, M. Vaillant, M. Gantenbein, N. De Bremaeker, C. Lieunard, T. Velez, M. Meyer, T. Guth, A. Kuemmerle, et al. 2013. A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial. Nutr. J. 12: 147.
225. Haffner, S. M., K. R. Tuttle, and D. L. Rainwater. 1991. Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care. 14: 302-307.
226. Levitsky, L. L., A. M. Scanu, and S. H. Gould. 1991. Lipoprotein(a) levels in black and white children and adolescents with IDDM. Diabetes Care. 14: 283-287.
227. Jenkins, A. J., J. S. Steele, E. D. Janus, and J. D. Best. 1991. Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes. 40: 787-790.
228. Bruckert, E., P. Davidoff, A. Grimaldi, J. Truffert, P. Giral, R. Doumith, F. Thervet, and J. L. De Gennes. 1990. Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA. 263: 35-36.
229. Couper, J. J., D. J. Bates, R. Cocciolone, A. M. Magarey, T. J. Boulton, J. L. Penfold, and R. G. Ryall. 1993. Association of lipoprotein(a) with puberty in IDDM. Diabetes Care. 16: 869-873.
230. Salzer, B., A. Stavljenic, G. Jurgens, M. Dumic, and A. Radica. 1993. Polymorphism of apolipoprotein E, lipoprotein(a), and other lipoproteins in children with type I diabetes. Clin. Chem. 39: 1427-1432.
231. Haffner, S. M., K. R. Tuttle, and D. L. Rainwater. 1992. Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism. 41: 116-120.
232. Jenkins, A. J., J. S. Steele, E. D. Janus, J. D. Santamaria, and J. D. Best. 1992. Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 35: 1055-1059.
233. Habib, S. S., and M. Aslam. 2004. Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 6: 338-343.
234. Singla, S., K. Kaur, G. Kaur, H. Kaur, J. Kaur, and S. Jaswal. 2009. Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control. Int. J. Diabetes Dev. Ctries. 29: 80-84.
235. Nakhjavani, M., A. Morteza, A. Esteghamati, O. Khalilzadeh, A. Zandieh, and R. Safari. 2011. Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes. Lipids. 46: 349-356.
236. Rainwater, D. L., J. W. MacCluer, M. P. Stern, J. L. VandeBerg, and S. M. Haffner. 1994. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes. 43: 942-946.
237. Habib, S. S., M. Aslam, S. F. Shah, and A. K. Naveed. 2009. Lipoprotein (a) is associated with basal insulin levels in patients with type 2 diabetes mellitus. Arq. Bras. Cardiol. 93: 28-33.
238. Boronat, M., P. Saavedra, N. Perez-Martin, M. J. Lopez-Madrazo, C. Rodriguez-Perez, and F. J. Novoa. 2012. High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc. Diabetol. 11: 81.
239. Ding, L., A. Song, M. Dai, M. Xu, W. Sun, B. Xu, J. Sun, T. Wang, Y. Xu, J. Lu, et al. 2015. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J. Lipid Res. 56: 920-926.
240. Ye, Z., P. C. Haycock, D. Gurdasani, C. Pomilla, S. M. Boekholdt, S. Tsimikas, K. T. Khaw, N. J. Wareham, M. S. Sandhu, and N. G. Forouhi. 2014. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes. 63: 332-342.
241. Purnell, J. Q., S. M. Marcovina, J. E. Hokanson, H. Kennedy, P. A. Cleary, M. W. Steffes, and J. D. Brunzell. 1995. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes. 44: 1218-1226.
242. Császár, A., H. Dieplinger, C. Sandholzer, I. Karádi, E. Juhász, H. Drexel, T. Halmos, L. Romics, J. R. Patsch, and G. Utermann. 1993. Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus. Diabetologia. 36: 47-51.
243. Klausen, I. C., E. B. Schmidt, H. H. Lervang, L. U. Gerdes, J. Ditzel, and O. Faergeman. 1992. Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 22: 538-541.
244. Haffner, S. M., P. A. Morales, M. P. Stern, and M. K. Gruber. 1992. Lp(a) concentrations in NIDDM. Diabetes. 41: 1267-1272.
245. Durlach, V., P. Gillery, E. Bertin, J. M. Taupin, H. Grulet, A. Gross, and M. Leutenegger. 1996. Serum lipoprotein (a) concentrations in a population of 819 non-insulin-dependent diabetic patients. Diabetes Metab. 22: 319-323.
246. Mora, S., P. R. Kamstrup, N. Rifai, B. G. Nordestgaard, J. E. Buring, and P. M. Ridker. 2010. Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 56: 1252-1260.
247. Rainwater, D. L., and S. M. Haffner. 1998. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler. Thromb. Vasc. Biol. 18: 1335-1341.
248. Neele, D. M., E. C. de Wit, and H. M. Princen. 1999. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia. 42: 41-44.
249. Calmarza, P., and J. C. Vella. 1999. Lipids, lipoproteins and apolipoprotein (a) isoforms in type 2 diabetic patients. J. Cardiovasc. Risk. 6: 171-175.
250. Ribault, A., M. R. Durou, C. Letellier, F. Wojcik, J. Y. Poirier, and A. Ruelland. 2000. Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients. Diabetes Metab. 26: 107-112.
251. Labudovic, D. D., K. N. Toseska, S. B. Alabakovska, and B. Todorova. 2003. Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus. Clin. Biochem. 36: 545-551.
252. Labudović, D. D., K. N. Toseska, S. B. Alabakovska, C. Dimitrovski, M. Jurhar, R. Isjanovska, M. Spiroski, and B. B. Todorova. 2003. Frequency distribution of apoprotein(a) isoforms in patients with diabetes mellitus and healthy subjects. Croat. Med. J. 44: 435-440.
253. Tsimikas, S., N. J. Viney, S. G. Hughes, W. Singleton, M. J. Graham, B. F. Baker, J. L. Burkey, Q. Yang, S. M. Marcovina, R. S. Geary, et al. 2015. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 386: 1472-1483.